Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Fielmann Aktie 280923 / DE0005772206

04.11.2025 08:00:03

Fielmann Group supports medical study by University Medical Center Hamburg-Eppendorf (UKE) on innovative eyecare


EQS-Media / 04.11.2025 / 08:00 CET/CEST

Fielmann Group supports medical study by University Medical Center Hamburg-Eppendorf (UKE) on innovative eyecare

  • Scientific evaluation of Fielmann’s Eye Health Checkup in Germany
  • Fielmann customers in Hamburg can now opt for an ophthalmologist exam as part of the scientific study

Together with Ocumeda, a leading tele-ophthalmological platform in Europe, Fielmann Group introduced the Eye Health Checkup, an innovative medical offering that makes eye health affordable and accessible for everyone. The service has been rolled out since 2024 and is currently being offered in all major Fielmann stores in Austria, Germany and Switzerland. 300,000 customers have already used the service and in 20% of the cases, conspicuous findings led to a recommendation for further checkups and treatments at local ophthalmologists and clinics.

This medical service is now being scientifically examined by the University Medical Center Hamburg-Eppendorf (UKE), supported by Fielmann with €600,000. The scientific study is led by the Director of the hospital’s Ophthalmology Department, Prof. Dr. Martin Spitzer. Its goal is to scientifically evaluate the tele-ophthalmological offering, comparing its results to those of a medical eye exam carried out in person by an ophthalmologist at the university clinic.

About the Eye Health Service at Fielmann
Fielmann’s Eye Health Checkup is a comprehensive eye health screening that is comprised of the most important measurements necessary to reliably detect major eye diseases: Certified Fielmann opticians document a medical history, carry out a refraction, take images of the retina and measure the intraocular pressure with state-of-the-art equipment in Fielmann stores. Subsequently, the data is digitally transferred to ophthalmologists who conduct an assessment and provide customers with feedback within one or two days. Patients with findings are referred to local ophthalmologists or clinics for further treatment. Appointments for an Eye Health Checkup can be scheduled online.

About the medical study – free ophthalmologist consultations for Fielmann customers
Starting November 1, 2025, all customers above the age of 18 who opt for an Eye Health Checkup at Fielmann stores in the metropolitan area of Hamburg will be offered the option to get their results validated free of charge and in person by an ophthalmologist at the University Medical Center Hamburg-Eppendorf (UKE). Appointments can be scheduled at short notice online. The comprehensive eye exam at UKE takes about two hours and the individual results will be submitted to the participant. Please note that participation in the study is only being offered to patients who have no known eye diseases. The results of the medical study will be published in 2027.

„Having your eye health checked regularly is important. More than 300,000 customers have already chosen the most convenient way – our medical Eye Health Checkup. By asking one of the most renowned medical research institutions in Europe to scientifically evaluate this innovative service, we underscore Fielmann’s commitment to delivering quality medical services in close collaboration with our partners in ophthalmology. This study marks another important milestone in our Vision 2035 growth strategy, which aims to make primary eyecare accessible and affordable. This way we pursue our purpose – to help everyone hear and see the beauty in the world”, says Marc Fielmann, CEO of the Fielmann Group.

Why primary eyecare is important
Studies indicate that a substantial proportion of severe visual impairment and blindness could be prevented through early diagnosis and regular ophthalmic examinations. According to estimates by the World Health Organization (WHO), up to 75% of all cases worldwide are preventable or treatable; in industrialized countries such as Germany, this proportion is approximately 40–50%. Nevertheless, only about one third of the population in Germany undergo regular eye health checkups. As a result, many preventable vision losses — particularly those caused by glaucoma, diabetic retinopathy, and age-related macular degeneration — are still detected too late. “This is why it is so important to understand if and how tele-ophthalmological offerings can contribute to identify patients that need ophthalmological care”, explains Prof. Dr. Martin Spitzer, Director of the study and of the Ophthalmology Department at the UKE.

The following Fielmann stores are offering the Eye Health Checkup and are participating in the scientific study:

      Hamburg-Barmbek-Nord
      Hamburg-Barmbek (EKZ)
      Hamburg-Bergedorf (Sachsentor)
      Hamburg-Billstedt
      Hamburg-Bramfeld
      Hamburg-City
      Hamburg-Eimsbuettel
      Hamburg-Eppendorf
      Hamburg-Farmsen
      Hamburg-Harburg
      Hamburg-Harburg III
      Hamburg-Langenhorn
      Hamburg-Osdorf (Elbe-EKZ)
      Hamburg-Othmarschen
      Hamburg-Ottensen
      Hamburg-Poppenbuettel
      Hamburg-Rahlstedt
      Hamburg-Schnelsen
      Hamburg-Volksdorf
      Hamburg-Wandsbek
 
      Ahrensburg
      Bad Oldesloe
      Bad Segeberg
      Buchholz
      Buxtehude
      Elmshorn
      Geesthacht
      Lueneburg (Grosse Baeckerstrasse)
      Moelln
      Norderstedt
      Pinneberg
      Seevetal
      Stade
      Wedel (Bahnhofstrasse)
 

Hamburg, Germany ? November 4, 2025
 

Fielmann Group AG

The Management Board

 

ABOUT FIELMANN GROUP AG
The Fielmann Group is a stock-listed German family business active in vision care and audiology, serving 30 million customers with eyewear, contact lenses, primary eyecare services and hearing aids. As one of the leading vision care providers worldwide, it operates an omnichannel platform consisting of digital sales channels and more than 1,200 stores in Europe and the United States. Founded in 1972, the company is led by Marc Fielmann, representing the second generation of the Fielmann family, which still owns the majority of the company’s stock. By staying true to its customer-centric values, the Fielmann Group helps everyone hear and see the beauty in the world. Thanks to the dedication of more than 24,000 people worldwide, the company consistently achieves customer satisfaction and retention rates of around 90% and has to date fitted more than 200 million pairs of individual prescription glasses.

ABOUT OCUMEDA AG
Ocumeda is one of the leading tele-ophthalmology platforms in Europe. Its mission: preventing vision loss and blindness for millions of people. The company was founded by an interdisciplinary team around renowned ophthalmologists, who were repeatedly confronted with patients with serious eye diseases that were in many cases diagnosed too late – with the consequence that vision loss was no longer avoidable. This observation was the impetus for founding Ocumeda, with the aim of making eye care accessible for everyone. To date, Ocumeda has already examined about 300,000 patients with its network of over 700 optical retail stores and ophthalmologists across Europe.

ABOUT UKE
Founded in 1889, the University Medical Center Hamburg-Eppendorf (UKE) is one of the most modern hospitals in Europe and, with around 16,100 employees, one of the largest employers in Hamburg, Germany. Every year, the UKE treats around 572,000 patients, 97,000 of whom are inpatients and 475,000 outpatients. The UKE's research focuses on neuroscience, cardiovascular research, health services research, oncology, and infections and inflammation. Through its medical faculty, the UKE trains around 3,500 doctors, dentists, and midwives. The Department of Ophthalmology, headed by Prof. Dr. Martin Spitzer, specializes in the diagnosis and treatment of complex eye diseases.

CONTACT

Katrin Carstens
Director Communications & Public Relations
press@fielmann.com
Phone +49 40 270 76-5907

 



End of Media Release


Issuer: Fielmann Group AG
Key word(s): Special Topics

04.11.2025 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Fielmann Group AG
Fuhlsbuettler Strasse 399
22309 Hamburg
Germany
Phone: +49 40 270 76-0
Fax: +49 40 270 76-390
Internet: www.fielmann-group.com
ISIN: DE0005772206
WKN: 577220
Indices: MDAX
Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart; Regulated Unofficial Market in Tradegate Exchange
EQS News ID: 2222812

 
End of News EQS Media

2222812  04.11.2025 CET/CEST

Analysen zu Fielmann AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
22.09.25 Fielmann Halten DZ BANK
18.09.25 Fielmann Hold Warburg Research
28.08.25 Fielmann Hold Warburg Research
18.07.25 Fielmann Halten DZ BANK
11.07.25 Fielmann Add Baader Bank
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’974.31 19.37 BP9SUU
Short 13’215.46 13.98 BU9S6U
Short 13’724.19 8.85 B19SNU
SMI-Kurs: 12’465.39 10.11.2025 17:30:00
Long 11’962.62 19.84 SNLBQU
Long 11’690.01 13.82 SSTBSU
Long 11’209.46 8.98 SQZB6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com